{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:57:31Z","timestamp":1764305851155,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mastocytosis is a heterogeneous group of disorders characterized by expansion and accumulation of clonal mast cells. Patients mainly present with either cutaneous lesions, anaphylaxis, or both. Its low prevalence and unusual features often hinder its diagnosis for several years. We report the case of an 18-year-old male who was referred to our department with a long-standing history of atypical skin lesions, allergic rhinitis, exercise-induced bronchoconstriction and what was believed to be food-related flushing and anaphylaxis, that was later diagnosed with mastocytosis. This case illustrates the need to consider investigating for mastocytosis when recurrent anaphylaxis is present, especially in the presence of atypical skin lesions, even if normal serum basal tryptase levels and allergic sensitization are present.<\/jats:p>","DOI":"10.3389\/fimmu.2021.635909","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T19:59:01Z","timestamp":1613246341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Mastocytosis: The Long Road to Diagnosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Tiago Azenha","family":"Rama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Lu\u00eds","family":"Pl\u00e1cido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Coimbra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"B1","first-page":"61","article-title":"Mastocytosis","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.adengl.2015.11.001","article-title":"Update on mastocytosis (Part 1): pathophysiology, clinical features, and diagnosis","volume":"107","author":"Aza\u00f1a","year":"2016","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)."},{"key":"B3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-27820-5_6","article-title":"Pediatric mastocytosis","volume-title":"Mastocytosis","author":"Alvarez-Twose","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology","volume":"137","author":"Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-3-030-27820-5_5","article-title":"Skin disease in mastocytosis","volume":"2020","author":"Thomas","year":"2020","journal-title":"Mastocytosis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Alvarez-Twose","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jaci.2015.05.034","article-title":"Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis","volume":"136","author":"Wiechers","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk Lymphoma."},{"key":"B10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s11882-014-0450-8","article-title":"Anaphylaxis as a clinical manifestation of clonal mast cell disorders","volume":"14","author":"Matito","year":"2014","journal-title":"Curr Allergy Asthma Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","article-title":"Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients","volume":"63","author":"Brockow","year":"2008","journal-title":"Allergy."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1365-2222.2007.02804.x","article-title":"Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)","volume":"37","author":"Gonz\u00e1lez de Olano","year":"2007","journal-title":"Clin Exp Allergy."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/all.12436","article-title":"Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis","volume":"69","author":"Valent","year":"2014","journal-title":"Allergy."},{"key":"B15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-0716-0696-4_27","article-title":"Identification and immunophenotypic characterization of normal and pathological mast cells","volume":"2163","author":"Morgado","year":"2020","journal-title":"Methods Mol Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest."},{"key":"B18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"B19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/ced.13408","article-title":"Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair(R))","volume":"43","author":"Hughes","year":"2018","journal-title":"Clin Exp Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.iac.2004.06.002","article-title":"Anti-IgE therapy","volume":"24","author":"Brownell","year":"2004","journal-title":"Immunol Allergy Clin North Am."},{"key":"B21","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nri914","article-title":"Regulation of mast-cell and basophil function and survival by IgE","volume":"2","author":"Kawakami","year":"2002","journal-title":"Nat Rev Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy."},{"key":"B23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.anai.2013.08.014","article-title":"Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis","volume":"111","author":"Matito","year":"2013","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2009","journal-title":"Allergy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.jaci.2011.04.009","article-title":"Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy","volume":"127","author":"Nadeau","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.anai.2018.02.018","article-title":"Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate","volume":"120","author":"Perino","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcgamma receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J Clin Invest."},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2016.01.005","article-title":"Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre","volume":"30","author":"Hermans","year":"2016","journal-title":"Eur J Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.iac.2006.05.006","article-title":"Systemic mastocytosis: clinical manifestations and differential diagnosis","volume":"26","author":"Butterfield","year":"2006","journal-title":"Immunol Allergy Clin North Am."},{"key":"B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/bjh.13789","article-title":"Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients","volume":"172","author":"Sanchez-Munoz","year":"2016","journal-title":"Br J Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1111\/jdv.15800","article-title":"Systemic mastocytosis with normal serum tryptase: rule or exception?","volume":"33","author":"Hermans","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.635909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T19:59:04Z","timestamp":1613246344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.635909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2021.635909"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.635909","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"article-number":"635909"}}